Inhibition of IRAK1 Is an Effective Therapy for Autoimmune Hypophysitis in Mice.

Abstract

Autoimmune hypophysitis (AH) is an autoimmune disease of the pituitary for which the pathogenesis is incompletely known. AH is often treated with corticosteroids; however, steroids may lead to considerable side effects. Using a mouse model of AH (experimental autoimmune hypophysitis, EAH), we show that interleukin-1 receptor-associated kinase 1 (IRAK1) is upregulated in the pituitaries of mice that developed EAH. We identified rosoxacin as a specific inhibitor for IRAK1 and found it could treat EAH. Rosoxacin treatment at an early stage (day 0-13) slightly reduced disease severity, whereas treatment at a later stage (day 14-27) significantly suppressed EAH. Further investigation indicated rosoxacin reduced production of autoantigen-specific antibodies. Rosoxacin downregulated production of cytokines and chemokines that may dampen T cell differentiation or recruitment to the pituitary. Finally, rosoxacin downregulated class II major histocompatibility complex expression on antigen-presenting cells that may lead to impaired activation of autoantigen-specific T cells. These data suggest that IRAK1 may play a pathogenic role in AH and that rosoxacin may be an effective drug for AH and other inflammatory diseases involving IRAK1 dysregulation.

• Authors: Hsiao-Chen Huang, Yun-Ti Chen, Han-Huei Lin, Zhi-Qin Li, Jinn-Moon Yang, Shey-Cherng Tzou
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 23 Issue 23 (Nov 29 2022) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 36499283 (Publication Type: Journal Article)

Chemical References

• Autoantigens
• Interleukin-1 Receptor-Associated Kinases
• Irak1 protein, mouse

Topics

• Autoantigens
• Autoimmune Hypophysitis (therapy)
• Interleukin-1 Receptor-Associated Kinases (antagonists & inhibitors)
• Animals
• Mice